Related Experiment Video

Updated: Jun 13, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Decision-making: stenting in acute myocardial infarction

Somjot S Brar1, Gregg W Stone

  • 1Regional Cardiac Catheterization Laboratory, 4867 Sunset Blvd, 3rd Floor, Room 3755, Kaiser Permanente Medical Center, Los Angeles, CA 90027, USA. SBrar@cvri.org

Future Cardiology
|May 14, 2010
PubMed

Insights

Percutaneous coronary intervention (PCI) rapidly restores blood flow in acute myocardial infarction (AMI), significantly reducing mortality and improving outcomes. Advances in drug-eluting stents and new medications enhance safety and efficacy for AMI patients.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Myocardial Infarction Management

Background:

  • Percutaneous coronary intervention (PCI) is crucial for acute myocardial infarction (AMI) management.
  • Early revascularization in evolving AMI reduces mortality, reinfarction, and infarct size.
  • Significant advancements in PCI technology and pharmacology have occurred since 1977.

Purpose of the Study:

  • To review the pivotal role and advancements in PCI for acute myocardial infarction.
  • To highlight the impact of improved stent technology and adjunct pharmacology on patient outcomes.
  • To address concerns regarding stent thrombosis and assess the benefits of new antithrombotic agents.

Main Methods:

  • Review of clinical trial and observational study data on PCI in AMI.
  • Analysis of outcomes associated with drug-eluting stents (DES).
  • Evaluation of safety and efficacy of new antithrombin and antiplatelet agents.

Main Results:

  • Primary PCI in AMI significantly reduces mortality, reinfarction, and improves myocardial salvage.
  • Drug-eluting stents markedly decrease restenosis rates.
  • New antithrombotic and antiplatelet agents reduce ischemic and hemorrhagic complications, improving event-free survival.

Conclusions:

  • PCI is a cornerstone in AMI management, with continuous improvements enhancing patient outcomes.
  • Drug-eluting stents have largely resolved early concerns about thrombosis in the AMI setting.
  • Modern pharmacotherapy further improves safety and survival following primary PCI for AMI.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...